[HTML][HTML] Phase I clinical trial of an autologous dendritic cell vaccine against HER2 shows safety and preliminary clinical efficacy
Background Despite recent advances, there is an urgent need for agents targeting HER2-
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
[HTML][HTML] Decoupling peptide binding from T cell receptor recognition with engineered chimeric MHC-I molecules
GF Papadaki, O Ani, TJ Florio, MC Young… - Frontiers in …, 2023 - frontiersin.org
Major Histocompatibility Complex class I (MHC-I) molecules display self, viral or aberrant
epitopic peptides to T cell receptors (TCRs), which employ interactions between …
epitopic peptides to T cell receptors (TCRs), which employ interactions between …
An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer
H Yu, C Ye, J Li, C Pan, W Lin, H Chen, Z Zhou… - Experimental Cell …, 2020 - Elsevier
MUC1 is a tumor-associated antigen (TAA) overexpressed in many tumor types, which
makes it an attractive target for cancer immunotherapy. However, this marker is a non …
makes it an attractive target for cancer immunotherapy. However, this marker is a non …
Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation
LRE Becher, WK Nevala, SL Sutor, M Abergel… - Blood …, 2020 - ashpublications.org
Human cytomegalovirus (HCMV) induces long-lasting T-cell immune responses that control
but do not clear infection. Typical responses involve private T-cell clones, expressing T-cell …
but do not clear infection. Typical responses involve private T-cell clones, expressing T-cell …